Know Labs Announces Bio-RFID™ Product Platform

Published: Oct 11, 2018

 
 

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – a provider of diagnostic solutions, released today a video highlighting the Company’s product pathway and platform. In the video CEO Phil Bosua discusses the Company’s Bio-RFID™ technological breakthrough and the plans for bringing the technology to market.

Here is a link to the video: https://youtu.be/ixceO5qt1M4

The transcript of Phil Bosua’s narrative in the video states in part:

“We originally set out to detect blood glucose and in turn, created a platform. We’ve begun initial research to measure all types of substances in the blood and interstitial fluid. Biomarkers like cortisol for stress levels, as well as continuous measurement of the luteinizing hormone, which would indicate ovulation within the next 4 hours – ideal for those wanting to get pregnant. We’re now ahead of schedule and look forward to creating the future of non-invasive health measurements.”

About Know Labs, Inc.

Know Labs, Inc., is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at www.knowlabs.co

Safe Harbor Statement

This video and release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

 

Contacts

Know Labs, Inc.
Jordyn Theisen, 319-321-8470
jordyn@knowlabs.co

 

 
 

Source: Know Labs, Inc.

Back to news